Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-a agent (infliximab), in inflammatory bowel diseases.

Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-a agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017 04; 45(8):1043-1057.

View in: PubMed

subject areas

Antibodies, Monoclonal
Anti-Inflammatory Agents
Biosimilar Pharmaceuticals
Colitis, Ulcerative
Crohn Disease
Databases, Factual
Female
Humans
Inflammatory Bowel Diseases
Infliximab
Male
Treatment Outcome

authors with profiles

Dejan Micic